SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022)

• Josep Gumà ^[1] ; Natalia Palazón-Carrión ^[5] ; Antonio Rueda-Domínguez ^[6] ; Silvia Sequero ^[2] ; Virginia Calvo ^[3] ; Ramón García-Arroyo ^[7] ; José Gómez-Codina ^[8] ; Marta Llanos ^[4] ; Natividad Martínez-Banaclocha ^[9] ; Mariano Provencio ^[3]
  1. [1] Hospital Universitari Sant Joan de Reus

     Hospital Universitari Sant Joan de Reus

     Reus, España

     
  2. [2] Hospital Universitario San Cecilio

     Hospital Universitario San Cecilio

     Granada, España

     
  3. [3] Hospital Universitario Puerta de Hierro

     Hospital Universitario Puerta de Hierro

     Madrid, España

     
  4. [4] Hospital Universitario de Canarias

     Hospital Universitario de Canarias

     San Cristóbal de La Laguna, España

     
  5. [5] Servicio de Oncología Médica, Hospital Universitario Virgen de la Macarena, Sevilla, España
  6. [6] UGCI Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, España
  7. [7] Servicio de Oncología Médica, Complejo Hospitalario Universitario, Pontevedra, España
  8. [8] Servicio de Oncología Médica, Hospital Universitari i Politècnic La Fe, Valencia, España
  9. [9] Servicio de Oncología, Hospital General Universitario Dr. Balmis, Instituto de Investigaciones Biomédicas y Sanitarias (ISABIAL), Alicante, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 9 (September), 2023, págs. 2749-2758
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Diffuse large B-cell lymphoma is the most frequent histological subtype of NHL and the paradigm for the management of aggressive lymphoma. An excisional or incisional lymph node biopsy evaluated by an experienced hemopathologist is recommended to establish the diagnosis. Twenty years following its introduction, R-CHOP remains the standard first-line treatment. No modification of this scheme (increased chemotherapy dose intensity, new monoclonal antibodies, or the addition of immunomodulators or anti-target agents) has significatively improved the clinical outcomes, whereas therapy for recurrence or progression is evolving rapidly. The irruption of CART cells, polatuzumab vedotin, tafasitamab, and CD20/CD3 bispecific antibodies are changing the natural history of relapsed patients and will challenge R-CHOP as the benchmark for newly diagnosed patients.